Orthopaedic Injection and DME Billing Denials: The Ancillary Revenue Practices Keep Losing in 2026

Injections and bracing are the two ancillary revenue streams most orthopaedic practices treat as afterthoughts, and they are the two most likely to be denied on technicalities that have nothing to do with clinical judgment. A viscosupplementation claim gets rejected because the JZ modifier was omitted, a modifier that reports zero waste and has been required since July 2023. A knee brace claim gets rejected because RT and LT were combined on one line instead of billed on two. A patient’s brace goes out the door without a prior authorization that CMS added to the required list in April 2026, with eight more codes joining on October 28, 2026. None of these are clinical failures. All of them are revenue you earned and did not collect. Here is the current rule set for both, and where the denials actually come from.

Why ancillary revenue is where denials concentrate

The macro picture first, because it frames the urgency. According to Kodiak Solutions’ analysis of CY2025 data spanning more than 2,300 hospitals and roughly 375,000 practice-based physicians, the initial claim denial rate rose to 11.6% in 2025 from 11.4% in 2024, and the median final denial rate rose to 2.7% from 2.5%. Kodiak attributes virtually all of the increase to clinical denials: precertification, prior authorization, and medical necessity. Net revenue lost to final denials and bad debt reached $48.4 billion in 2025, up 25% from $38.6 billion the year prior.

Experian Health’s 2025 State of Claims survey found that 41% of providers now face denial rates of 10% or higher, a figure that has grown every year since 2022, with missing or inaccurate data cited as the top denial reason at 50%.

Injections and DME sit precisely at the intersection of those two trends. They are prior-authorization-heavy and they are data-heavy. Every claim carries a drug code, a unit count, a waste modifier, an NDC, a diagnosis that must satisfy an LCD, and often a KX attestation. There are more places for the claim to be wrong than there are for a straightforward office visit.

Part 1: Injection and viscosupplementation billing

The CPT layer: 20600 through 20611

Six codes, split by joint size and by whether ultrasound guidance was used:

• Small joints or bursae (fingers, toes): 20600 without ultrasound guidance, 20604 with ultrasound guidance
• Intermediate joints or bursae (temporomandibular, acromioclavicular, wrist, elbow, ankle, olecranon bursa): 20605 without ultrasound guidance, 20606 with ultrasound guidance
• Major joints or bursae (shoulder, hip, knee, subacromial bursa): 20610 without ultrasound guidance, 20611 with ultrasound guidance

Three rules govern this family, and each one generates denials:

The permanent image requirement. The CPT descriptor for the ultrasound-guided codes requires permanent recording and reporting of the ultrasound image. No saved image, no ultrasound code. You report 20600, 20605, or 20610 instead. Practices that adopt in-office ultrasound and do not build image archiving into the workflow bill 20611 for months and then lose it all on audit.

76942 is not separately reportable with any of the “with ultrasound guidance” codes. The guidance is in the code.

One unit per joint per session. NCCI Chapter IV, Section H.7 states that the unit of service “is a joint and its surrounding bursae, if any,” and that a provider “shall not report more than one unit of service for arthrocentesis of any one joint regardless of whether or not the physician also aspirates or injects one or more of its surrounding bursae.” Aspirate and inject the same knee in one session? One unit. Inject the knee and the surrounding bursa? Still one unit.

Two additional NCCI rules to know. Section I.17 prohibits reporting arthrocentesis separately with an open or arthroscopic joint procedure on the same joint. Section H.6, drawing on the Medicare Claims Processing Manual (Pub. 100-04, Chapter 12), requires bilateral procedures to be reported with modifier 50 and one unit of service on a single claim line unless the descriptor is inherently bilateral. Two caveats worth flagging to your team: this is a Medicare convention, and a number of commercial payers instead require two lines with LT and RT or modifier 50 with two units, so payer policy has to be checked. And it differs from the DME rule below, which is a frequent source of confusion when the same staff handle both.

For distinct joints injected in the same session where an edit fires, XS (separate structure) is the technically correct modifier. CMS’s April 2026 guidance directs providers to use the X{EPSU} set instead of modifier 59 wherever possible, reserving modifier 59 for cases where no more specific modifier applies.

The drug layer: J-codes, units, and the modifiers that reject claims

Viscosupplementation is billed under the “buy and bill” model. The practice purchases the product and bills Medicare, which pays under Part B at ASP plus 6 percent, published quarterly and reduced in practice by sequestration. That spread is the practice’s entire margin on the product, which is why a denied drug claim is not a small loss. You have already paid for the vial.

Unit conventions differ by product and are a recurring source of error. Per CMS coverage article A56157 (Revision 9, effective June 25, 2026):

• Per-dose (1 unit per injection): J7321 (Hyalgan/Supartz/Visco-3), J7323 (Euflexxa), J7324 (Orthovisc), J7326 (Gel-One), J7327 (Monovisc)
• Per-milligram: J7318 (Durolane, 60 units), J7320 (Genvisc 850, 25 units per weekly injection), J7322 (Hymovis 24 units, Hymovis One 32 units), J7325 (Synvisc 16 units, Synvisc-One 48 units), J7329 (TriVisc, 25 units per weekly), J7331 (Synojoynt, 20 units per weekly), J7332 (Triluron, 20 units per weekly)
• Per 0.1 milligram: J7328 (Gelsyn-3, 168 units per weekly injection)

Two modifiers carry outsized denial risk:

EJ is required on subsequent injections within a series, and it must not be appended to the first injection of each series. Omitting it on injections two and three of a three-injection course invites a duplicate-claim edit. Note that EJ is imposed by MAC billing and coding articles rather than by a nationally uniform HCPCS rule, so confirm the language in your own MAC’s article.

JW and JZ are the ones that quietly reject claims. JW reports drug discarded and not administered. JZ reports zero drug wasted. JZ became available January 1, 2023 and was required no later than July 1, 2023; since October 1, 2023, CMS has returned single-dose container claims that lack a proper JW or JZ modifier as unprocessable until they are corrected. The point worth repeating to your billing team: JZ is not optional.

A perfectly administered single-dose vial with no waste still requires a modifier, the one that says there was no waste. Discarded amounts must be documented in the medical record. The requirement applies to separately payable Part B drugs from single-dose containers or single-use packages, with carve-outs for vaccines, RHC and FQHC settings, inpatient claims under IPPS, and drugs packaged under OPPS or ASC payment.

On NDC reporting: the federal mandate to report NDCs for physician-administered drugs is a Medicaid requirement, rooted in the Deficit Reduction Act of 2005 and Section 1927(a)(7)(B)(i) of the Social Security Act, with states losing federal matching payments if they fail to collect it. Most commercial payers impose their own NDC requirements by contract. Frame your internal policy as “Medicaid federally, plus most commercial payers by contract” rather than assuming a universal Part B rule.

The coverage layer: why viscosupplementation gets denied

Medicare covers hyaluronic acid injections narrowly, and the LCDs are specific. Palmetto GBA’s LCD L39260 requires all of the following to be documented:

1. Symptomatic osteoarthritis with “pain that interferes with functional activities (such as, ambulation and prolonged standing)”
2. Radiographic evidence, meaning joint space narrowing, subchondral sclerosis, osteophytes, or subchondral cysts
3. Failed conservative therapy for a minimum of three months, both non-pharmacologic (physical therapy, exercise, weight management, bracing) and pharmacologic (acetaminophen, oral or topical NSAIDs, topical capsaicin)
4. Failed intra-articular glucocorticoid injections, or a documented contraindication

Repeat series require a minimum of six months between courses plus documented symptom recurrence and documented improvement from the prior series. Covered diagnoses are limited to the knee osteoarthritis codes M17.0, M17.11, M17.12, M17.2, M17.31, M17.32, M17.4, and M17.5.

WPS LCD L39529 adds an explicit non-covered list that catches practices off guard: doses or frequencies exceeding accepted recommended dosage; concurrent intra-articular corticosteroid injections without documented medical necessity; non-knee joints, so hip and shoulder viscosupplementation are not covered; imaging guidance beyond fluoroscopy or ultrasound; switching between different hyaluronan agents mid-course; post-arthroplasty or perioperative use; and non-osteoarthritis diagnoses.

The failure mode here is almost never clinical. It is documentary. The three months of conservative therapy happened, but the note says “failed conservative management” instead of naming the modalities and the duration. CMS article A56157 is explicit about the consequence: “Claims submitted without requested supporting evidence in the medical record will be denied as being not medically necessary.”

Note also that prior authorization for viscosupplementation is a commercial payer and Medicare Advantage requirement, not a Traditional Medicare one. Given that Kodiak found Medicare Advantage final denial rates of 5.0% versus 1.9% for Traditional Medicare, your MA mix largely determines how much prior auth burden this service line carries.

Part 2: Bracing, orthotics, and the October 28 prior auth expansion

The prior authorization calendar is the story

CMS has been steadily expanding required prior authorization for orthoses, and orthopaedic practices that dispense braces in-office are directly in scope. The timeline, per CMS’s DMEPOS prior authorization program page and the underlying Federal Register notices:

• April 13, 2022. Phased rollout begins for five orthoses codes: L0648 and L0650 (lumbar-sacral orthoses) and L1832, L1833, and L1851 (knee orthoses). Nationwide by October 10, 2022.
• August 12, 2024. Six additional orthoses codes added: L0631, L0637, L0639 (lumbar-sacral orthoses, custom fitted), L1843 and L1845 (knee orthoses, custom fitted), and L1951 (ankle-foot orthosis, prefabricated). L1833 removed from the Master List and therefore from the required list.
• April 13, 2026. Five new orthoses codes added nationwide: L0651 (lumbar-sacral orthosis), L1844, L1846, and L1852 (knee orthoses), and L1932 (ankle-foot orthosis). Two segmental pneumatic compressor codes, E0651 and E0652, were added the same day.
• October 28, 2026. Eight codes added: L0456, L0457, and L0486 (thoracic-lumbar-sacral orthoses), L1833 returning to the list, upper-limb orthoses L3761 (elbow) and L3916 (wrist-hand), plus E0194 (air fluidized bed) and K0005 (ultra-lightweight manual wheelchair). L3761 and L3916 phase in by state, starting with New York, Michigan, Florida, and California on October 28, 2026, then adding a second group on January 26, 2027 and going nationwide April 26, 2027.

Note the code families here, because the shorthand “brace prior auth” hides real variety. L0456, L0457, L0486, L0631, L0637, L0639, L0648, L0650, and L0651 are spinal orthoses. L1832, L1833, L1843, L1844, L1845, L1846, L1851, and L1852 are knee orthoses. L1932 and L1951 are ankle-foot orthoses, and L3761 and L3916 are upper-limb.

Review timeframes are no more than seven calendar days for standard requests (effective January 1, 2025), with MACs operationally targeting five business days, and two business days for expedited. Affirmative decisions are valid for 60 days.

A supplier exemption process took effect June 1, 2026 for suppliers that achieved a 90% or higher provisional affirmation rate on initial prior authorization requests, with a minimum of ten initial requests, during the June 1 through November 30, 2025 measurement period. It is calculated by PTAN and jurisdiction, runs through May 31, 2027, and renews annually, with a post-payment sample review required to keep it. Worth pursuing if your brace volume is meaningful, because it removes the prior auth requirement entirely for qualifying suppliers.

The October 28 additions land in the middle of Q4. If your practice dispenses spinal orthoses or upper-limb bracing, the workflow needs to be built in October, not discovered in November.

The KX modifier rule: three modifiers, no fourth option

CMS’s Knee Orthoses Policy Article A52465 (revision effective January 25, 2026) sets the rule clearly. Suppliers must append KX to knee orthosis base and addition codes only if all coverage criteria in the related LCD are met and documented. If criteria are not met, use GA (advance beneficiary notice obtained) or GZ (no ABN).

Claim lines submitted without KX, GA, or GZ are rejected as missing information. There is no fourth option, including “no modifier.”

The RT/LT rule that contradicts the injection rule

This trips up practices constantly because it is the opposite of the CPT bilateral convention. For bilateral DME items with the same code on identical dates of service, bill each on a separate claim line using RT and LT modifiers with one unit of service per line. Per CMS, an RTLT modifier on one line with two units of service will be rejected as incorrect coding.

Compare: bilateral injections use modifier 50 with one unit on one line. Bilateral braces use two lines, RT and LT, one unit each. Same patient, same visit, opposite conventions.

Off-the-shelf vs. custom-fitted: “minimal self-adjustment”

The determining criterion between OTS and custom-fitted codes is whether the item requires more than minimal self-adjustment. Per CMS coverage articles, L1833 and L1851 are off-the-shelf and L1832 is custom-fitted, requiring modification performed by a certified orthotist or an individual with specialized training, with the specific modifications documented at delivery. Off-the-shelf adjustments are limited to things like assembling, trimming, or adjusting straps. Custom-fitted items must be trimmed, bent, molded, or otherwise modified for individualized fit.

Documentation requirements are code-specific and stricter than most practices assume. For L1832, L1833, and L1850, the record must document a physical knee examination including joint laxity tests performed and a description of exam findings supporting objective joint laxity. For L1843, L1844, L1845, L1846, L1851, and L1852, the record must document ambulatory status plus appropriate exam findings.

The enrollment trap: every location needs its own CMS-855S

This one is expensive when it is missed. A physician practice that dispenses DMEPOS cannot simply add a new location to its practice enrollment. Under 42 CFR 424.57(b), each location dispensing DMEPOS must be individually enrolled as a DMEPOS location in Medicare via form CMS-855S through PECOS. Only locations used solely as warehouses or repair facilities are exempt. A surety bond exception at 424.57(d)(15) may apply to physicians and non-physician practitioners furnishing DMEPOS only to their own patients as part of their professional service, but that is a bond exception, not an enrollment exception.

For a growing orthopaedic group opening satellite clinics, this is a routine and costly oversight. Braces dispensed from an unenrolled location are not payable.

The audit environment

Orthotic bracing is under active OIG scrutiny, which is worth knowing before you scale the service line. OIG report A-09-21-03019, issued May 2024 and covering CY2018 through CY2020, found Medicare paid nearly $1.9 billion for off-the-shelf orthotic braces, with $66.4 million paid for potentially unallowable replacement braces lacking required modifiers, and over $1 billion paid for braces ordered by providers with no treating relationship to the beneficiary.

A separate October 2025 OIG report on DMEPOS furnished during inpatient stays (OAS-24-09-005) found a 100% error rate across 114,323 items worth $22.7 million billed between January 2018 and December 2024, with prosthetics and orthotics accounting for $12.3 million, or 55%, of the improper payments.

The practical read for a legitimate orthopaedic practice: your documentation of the treating relationship, the exam findings, and the modifier set is what separates you from the population OIG is targeting. Do not let a compliant service line get caught in an enforcement sweep because of missing modifiers.

One note on rates. The CY2026 DMEPOS fee schedule covered item update was a net 2.0% increase, reflecting a CPI-U of 2.7% for the 12 months ending June 30, 2025 less a 0.7% productivity adjustment, effective January 1, 2026.

Frequently asked questions

Do I need the JZ modifier if there is no drug waste?

Yes. JZ specifically reports that zero drug was wasted or discarded. It became required on July 1, 2023, and since October 1, 2023 CMS has returned claims for drugs from single-dose containers that lack either JW (waste occurred) or JZ (no waste) as unprocessable until they are corrected. JZ is mandatory when there is no waste. It is not an optional attestation.

Can I bill 20610 twice for injecting both knees?

Not as two units on two lines, at least not for Medicare. Per NCCI Chapter IV, bilateral surgical procedures must be reported with modifier 50 and one unit of service on a single claim line unless the code descriptor defines the procedure as bilateral. Some commercial payers require two lines with LT and RT, or modifier 50 with two units, so check the contract. Note this is also the opposite of the DME convention, where bilateral braces are billed on two separate lines with RT and LT.

Why was my viscosupplementation claim denied for medical necessity?

The most common cause is documentation that does not affirmatively establish all four LCD criteria: symptomatic osteoarthritis with functional interference, radiographic evidence, a minimum of three months of failed conservative therapy (both non-pharmacologic and pharmacologic, named specifically), and failed intra-articular glucocorticoid injections or a documented contraindication. Notes that say “failed conservative management” without naming modalities and duration do not support the claim.

Is viscosupplementation covered for the hip or shoulder?

Not under Medicare. WPS LCD L39529 explicitly lists non-knee joints as non-covered, and the covered diagnosis list is limited to knee osteoarthritis codes (M17.0, M17.11, M17.12, M17.2, M17.31, M17.32, M17.4, M17.5). Switching between different hyaluronan agents mid-course is also non-covered.

Which orthosis codes require prior authorization in 2026?

The required list has expanded in stages, and it covers more than knee braces. L0648 and L0650 (spinal) plus L1832 and L1851 (knee) were included from April 2022, with L1833 removed in August 2024. Six codes were added in August 2024: L0631, L0637, L0639, L1843, L1845, and L1951. Five orthoses codes were added April 13, 2026: L0651, L1844, L1846, L1852, and L1932. Eight more are added October 28, 2026: L0456, L0457, L0486, L1833 (returning), L3761, L3916, E0194, and K0005, with L3761 and L3916 phasing in by state. Standard review is no more than seven calendar days; expedited is two business days. Check the current CMS required prior authorization list before dispensing.

What happens if I submit a knee orthosis claim without a KX modifier?

The line is rejected as missing information. CMS requires KX when all LCD coverage criteria are met and documented, GA when criteria are not met and an ABN was obtained, or GZ when criteria are not met and no ABN was obtained. A claim line with none of the three is not processable.

Does each of my clinic locations need separate DMEPOS enrollment?

Yes. Every location that dispenses DMEPOS must be individually enrolled in Medicare as a DMEPOS location using form CMS-855S through PECOS. Adding the location to your existing practice enrollment is not sufficient. Only locations used solely as warehouses or repair facilities are exempt.

The pattern underneath all of this

Read the rules above together and a pattern emerges. Almost none of the denials described here involve a disagreement about whether the care was appropriate. They involve a missing modifier, a unit convention applied from the wrong code family, a documented exam that did not name the specific finding a policy requires, or a prior authorization requirement that changed on a date nobody flagged.

That is a systems problem. The AMA’s 2025 prior authorization survey found physicians and staff spending an average of 13 hours per week on prior authorization and completing an average of 40 prior authorizations per week, with two in five practices employing staff who work exclusively on prior auth. Adding more of that labor to catch a JZ modifier is not a strategy.

Maia’s Prior Auth Reconciliation module reports a 25% to 35% efficiency gain, and the AutoCoder populates codes, modifiers, and clinical justification inside the EHR (Athena, eClinicalWorks, Epic, ModMed, NextGen, or Tebra) before a human coder opens the chart. The modifier that reports zero waste gets appended because the system knows the vial was single-dose, not because someone remembered.

See how Maia’s AutoCoder handles this automatically for orthopaedic practices. Book a demo at usemaia.com.